Related Experiment Video
Updated: Jun 1, 2026
09:16
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Low dose methamphetamine mediates neuroprotection through a PI3K-AKT pathway
Thomas F Rau1, Aakriti Kothiwal, Li Zhang
1Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA.
Neuropharmacology
|June 4, 2011
Summary
Low doses of methamphetamine offer neuroprotection against stroke by activating dopamine receptors. This pathway involves PI3K/AKT signaling, reducing cell death and improving outcomes in stroke models.
Area of Science:
- Neuroscience
- Pharmacology
- Stroke Research
Background:
- High-dose methamphetamine causes dopamine-related neurotoxicity.
- Moderate dopamine receptor activation can be neuroprotective.
- The potential neuroprotective effects of low-dose methamphetamine in stroke models are unexplored.
Purpose of the Study:
- To investigate the hypothesis that low doses of methamphetamine induce neuroprotection in stroke models.
- To elucidate the underlying molecular mechanisms of methamphetamine-mediated neuroprotection.
Main Methods:
- In vitro: Rat organotypic hippocampal slice cultures subjected to oxygen-glucose deprivation (OGD).
- In vivo: Rat model of embolic middle cerebral artery occlusion (MCAO).
- Pharmacological inhibition of dopamine receptors and PI3K pathway; assessment of behavioral outcomes, apoptosis markers, and signaling pathway activation (AKT).
Main Results:
- Methamphetamine demonstrated a robust, dose-dependent neuroprotective effect in both OGD and MCAO models.
- Neuroprotection was associated with dopamine receptor (D1/D2) activation and subsequent PI3K/AKT pathway signaling.
- Methamphetamine treatment reduced cleaved caspase-3 and TUNEL staining, indicating decreased apoptosis.
- Delayed administration of methamphetamine up to 12 hours post-MCAO improved behavioral outcomes.
Conclusions:
- Low-dose methamphetamine confers significant neuroprotection in experimental stroke models.
- The protective mechanism involves dopamine receptor activation, PI3K/AKT signaling, and apoptosis inhibition.
- Methamphetamine represents a potential therapeutic agent for stroke, warranting further investigation.
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:17Phase II Reactions: Methylation Reactions
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...